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Abstract
Background: The development of a video assisted thoracic surgery lobectomy (VATS-L) program provides a
dedicated surgical team with a recognized learning curve (LC) of 50 procedures. We analyse the results of our
program, comparing the LC with subsequent cases.
Methods: From June 2012 to March 2015, we performed n = 146 VATS major pulmonary resections: n = 50 (Group
A: LC); n = 96 (Group B). Pre-operative mediastinal staging followed the National Comprehensive Cancer Network
guidelines. All procedures were performed using a standard anterior approach to the hilum; lymphadenectomy
followed the NCCN recommendations. During the LC, VATS-L indication was reserved to clinical stages I, therefore
evaluated case by case.
Results: Mean operative time was 191 min (120-290) in Group A and 162 min (85-360) in Group B (p <0,01).
Pathological T status was similar between two Groups. Lymphadenectomy included a mean of 5.8 stations in
Group A and 6.6 in Group B resulting in: pN0 disease: Group A n = 44 (88 %), Group B n = 80 (83.4 %); pN1:
Group A n = 3 (6 %), Group B n = 8 (8.3 %); pN2: Group A n = 3 (6 %), Group B n = 8 (8.3 %). Conversion rate
was: 8 % in group A (n = 4 vascular injuries); 1.1 % in Group B (n = 1 hilar lymph node disease). We registered
n = 6 (12 %) complications in Group A, n = 10 (10.6 %) in Group B. One case (1.1 %) of late post-operative
mortality (90 days) was registered in Group B for liver failure. Mean hospital stay was 6.5 days in Group A
and 5.9 days in Group B.
Conclusions: We confirm the effectiveness of a VATS-L program with a learning curve of 50 cases performed
by a dedicated surgical team. Besides the LC, conversion rate falls down, lymphadenectomy become more
efficient, indications can be extended to upper stages.
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Background
Since its introduction in 1991 [1], video assisted thor-
acic surgery lobectomy (VATS-L) for non-small cell
lung cancer (NSCLC) has evolved to become a safe and
effective alternative to the conventional thoracotomy
approach [2, 3]. VATS-L, compared with lobectomy by
thoracotomy, is associated with a shorter length of stay,
less postoperative pain, preserved pulmonary function,
fewer postoperative complications and better compli-
ance with adjuvant chemotherapy [4–6]. Despite these
advantages, recent data from European Society of
Thoracic Surgeon database demonstrated that thoraco-
tomic lobectomy is still the procedure of choice for sur-
gical treatment of NSCLC and only 10 % (2721 vs
26051) of all procedures from 2007 to 2013 were per-
formed with a minimally invasive approach [7]. Even if
this circumstance may be related more to a cultural
background, many authors report VATS-L as a more
complex and time consuming procedure, with poten-
tially serious intra-operative complications, moreover
questioning its oncologic value particularly during the
learning curve (LC) period. In this setting, many surgi-
cal teams could be demotivated in pursuing a VATS-L
program. The length of a VATS-L LC has been estab-
lished in 50 procedures [8]. However, several factors
can affect duration and efficacy of the LC period: the
experience in other complex VATS procedures and/or
in standard open major pulmonary resections; the se-
lection of a dedicated surgical team; the opportunity to
concentrate the LC procedures within a short period
and, last but not least, the development of a proctored
and stepwise program [9–11].
In our series we analysed surgical and oncological out-
comes (mortality, morbidity, hospitalization, operative
time, type of resections, safety and effectiveness of medias-
tinal lymph node dissection and intra-operative staging) of
a VATS-L program comparing the first 50 patients, repre-
senting our LC, with subsequent cases.
Methods
Our institutional review board granted approval and
waived the requirement for specific informed consent
for this retrospective study. This is a retrospective study
using a prospective database of consecutive patients who
underwent VATS major pulmonary resections (VMPR)
for NSCLC at our institution (Thoracic Surgery Unit,
University Hospital Careggi, Florence) from June 2012
to March 2015.
Each patient was pre-operatively evaluated by com-
puted tomography (CT) scan, positron emission tomog-
raphy (PET) scan or PET/CT, pulmonary function test
and bronchoscopy. Cervical video-mediastinoscopy
(VM) was performed according to National Comprehen-
sive Cancer Network (NCCN) guidelines (v. 2.2010): T >
3 cm, cN1 disease, central location [12]. VM was
planned as a same-day surgical procedure, with frozen
section (FS) analysis of lymph node biopsies in order to
decide whether to proceed to lobectomy or to abort. A
dedicated team, composed by two staff surgeons and
two residents, was identified as in charge for the VATS-
L program; team members were selected on the basis of
a previous experience with other complex VATS proce-
dures and a previous attendance at qualified training
course on VATS-L. For the very first procedures (i.e. 10
cases), the two staff surgeons worked together, as first
surgeon and first assistant. After this period, the team
was composed by one staff surgeon and by the residents.
Only in selected cases, the second staff surgeon was in-
volved in the procedure. After completion of the LC,
other staff surgeons of the division were invited to grad-
ually join the program. The anaesthesiological team was
composed by two staff anesthesiologists, with experience
in the field of thoracoscopic procedures.
The first 50 cases of VATS-L (LC –Group A) were se-
lected on the criterion of NSCLC at clinical Stage I,
without endobronchial involvement at pre-operative
bronchoscopy. Since the VATS-L program start-up,
every case with these features referred to our division,
was evaluated and eventually treated by the VATS-L
team. After completion of the LC, also more advanced
stages, considered as potentially resectable by VATS,
were discussed and eventually included in the VATS-L
program. Centrally located tumours, with the potential
need of a bronchoplasty procedure, were always
excluded.
All procedures were performed by a standardized
three-port anterior approach, as previously described by
Hansen et al [13]. No tissue retractor or rib spreading
was used; in selected cases (e.g. obese patients) a wound
protector (Alexis, Applied Medical, USA) was applied at
the site of the utility incision. Lymph node dissection
followed the NCCN (version 2.2010) recommendations
[12]: “minimum of 3 N2 stations sampled or complete
lymph node dissection”. In case of conversion, the
anterior utility incision was extended to an anterolat-
eral thoracotomy. We used extensively paravertebral
block with single injection of local anesthetics (ropi-
vacaine 75-100 mg plus lidocaine 200 mg) in several
different intercostal spaces associated with intraven-
ous administration of paracetamol/acetaminophen or
non-steroidal anti-inflammatory drugs (NSAIDs) in
the post-operative period.
Our policy for removing chest tubes is to take out
them in absence of air leak and less than 200 mL of li-
quid output in 24 h.
Group A and Group B were compared in terms of sur-
gical results (type of resection, operative time, blood
loss, chest tube duration, hospital stay, intra-operative
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complications and conversions, postoperative morbidity
and mortality) and oncological results (histology, pTNM,
lymphadenectomy).
Statistical analysis was performed using SPSS 16.0 soft-
ware (SPSS Inc., Chicago, IL). Continuous variables are
expressed as mean values ± SD or median and range.
Categorical variables were analysed using χ-square test.
Continuous variables were compared by Student’s t test.
A P value <0.05 was considered statistically significant.
Results
We prospectively recorded data from 146 scheduled
VMPRs chronologically divided into two groups: the first
50 cases, representing the LC (Group A), and the subse-
quent 96 cases, considered as a control group (Group
B). The whole program (Group A and Group B) was ini-
tiated and completed by the same surgical team.
Demographical and pre-operative data are depicted in
Table 1. There were no differences in the demographic
and clinic-pathologic factors between the two groups.
Since the different inclusion criteria, induction treat-
ments are represented only in Group B. Type of resec-
tions and oncological results are showed in Table 2.
According to 2.2010 NCCN pre-operative mediastinal
staging guidelines [12], n = 27/146 (18.5 %) patients
underwent VM with FS analysis of bioptic samples and,
if negative, VMPR was planned as a same-day surgical
procedure. FS sections showed a 0 % of both, false posi-
tive and false negative results. About type of resection,
we observed a predominance of upper lobe lobectomies,
equally distributed into the two groups. In Group B we
performed a higher number of major lung resections dif-
ferent from lobectomies: 6.3 % (n = 6) versus 2 % (n = 1)
in Group A. Particularly, in Group B we had: n = 1
(1.1 %) superior bilobectomy, for a double lesion of the
upper and middle lobe, clinically N0; n = 1 (1.1 %) left
pneumonecotmy, again for a double lesion involving re-
spectively the upper and lower lobe, with endobron-
chial lesion at the level of the interlobar carina. Both
groups were balanced for NSCLC histology. About
pTNM, due to a selection bias, we obviously observed a
prevalence of early stages (78 % stage I, 13 % stage II)
in Group A, even if without statistically significance.
Due to widening of surgical indications, in Group B we
operated more advanced stages (T4 lesions in n = 3
patients).
About results of VATS intra-operative lymphadenec-
tomy, the mean number of hilar and mediastinal dis-
sected lymph node stations statistically differ between
the two groups (Table 2).
Table 1 Demographical and pre-operative data
Variables Group A (LC) Group B P
Age (years) 67 ± 7,1 66 ± 9,5 NS
Sex male 25 (50 %) 57 (59 %) NS
Co-morbid disease
Hypertension 23 (46 %) 53 (55,2 %) NS
Heart disease 9 (18 %) 20 (20,8 %)
Diabetes 1 (2 %) 4 (4,2 %)
COPD 5 (10 %) 11 (11,4 %)
Current smokers 18 (36 %) 34 (35,4 %)
Neo-adiuvant treatment 0 (0 %) 6 (6,3 %)
Pulmonary function
FEV1% 76 % 70 % NS
DLCO% 75 % 69 %
NS not significant
Table 2 Pre-operative video-mediastinoscopy, type of VATS
major pulmonary resection, final histological diagnosis, p-stage
and intra-operative lymphadenectomy




11 (22 %) 16 (16,6 %) NS
RUL 15 (30 %) 33 (34,3 %)
ML 3 (6 %) 4 (4,2 %)
RLL 10 (20 %) 18 (18,7 %)
LUL 16 (32 %) 15 (15,6 %)
LLL 5 (10 %) 20 (20,8 %)
Upper bilobectomy 0 1 (1,1 %)
Left Pneumonectomy 0 1 (1,1 %)
Segmentectomy 1 (2 %) 4 (4,2 %)
Histology
Adenocarcinoma 33 (66 %) 71 (74 %) NS
Squamous cell carcinoma 12 (24 %) 15 (15,6 %)
Others 5 (10 %) 10 (10,4 %)
• Large cell carcinoma 1 3
• Carcinoid 4 7
Pathological T stage
1a 26 (52 %) 41 (42,7 %) NS
1b 17 (34 %) 21 (21,8 %)
2a 6 (12 %) 18 (18,8 %)
2b 0 6 (6,3 %)
3 0 7 (7,3 %)
4 1 (2 %) 3 (3,1 %)
Pathological N stage
0 44 (88 %) 80 (83,4 %) NS
1 3 (6 %) 8 (8,3 %)
2 3 (6 %) 8 (8,3 %)
Number of nodal station removed 5,78 ± 0,9 6,55 ± 1,1 <0,01
NS not significant
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Surgical data and post-operative outcomes are showed
in Table 3. The operative time (detailed for each patient
in Fig. 1) was statistically significantly shorter in Group
B. There was a not statistically significant difference be-
tween the estimated blood loss in the two groups (Fig. 2).
The conversion rate was statistically significantly lower
in Group B than in Group A (1 % vs 8 % respectively,
p = 0,02). Conversions were due to vascular injuries in
all cases of Group A: they were n = 3 (6 %) bleeding
(arterial bleeding n = 2, 4 %; venous bleeding n = 1,
2 %), of which n = 2 (4 %) considered as “bleeding not
safely manageable by VATS” and n = 1 (2 %) as a “life
threatening bleeding”. Finally, n = 1 (2 %) conversion
in Group A was due to an incorrect transection of the
main left pulmonary artery instead of the upper medi-
astinal branch during a left upper lobe lobectomy;
after conversion, this patient was managed by an end
to end anastomosis of the vascular stumps. In Group B,
n = 1 (1.1 %) conversion was due to an hilar lymphadenop-
athy. Complication rates were similar between the two
groups. We registered n = 2 major complications, both in
Group B: n = 1 acute lung injury (ALI); n = 1 acute liver
failure, evolved with a multiple organ failure (MOF). This
last patient represented the n = 1 case of mortality in
Group B. Chest drain duration and hospital stay (Group A
6,5 ± 2,5 vs Group B 5,9 ± 1,9; range 4-12 vs 4-28) were
similar between the two groups; n = 68 (46 %) patients
were discharged within the fifth p.o. day. Our policy in re-
moving chest tubes is to take out them when the drained
is less of 200 ml in the last 24 h and this can affect directly
the hospitalization.
Discussion
VATS-Lobectomy, is recognized to be associated with
many advantages compared with lobectomy by thoracot-
omy [2–4, 14, 15]. Recent analysis of postoperative out-
comes performed on both, single institutional series and
official database, proposed VATS-L as to be superior in
terms of length of stay, postoperative pain, preserving pul-
monary function, postoperative complications and com-
pliance with adjuvant chemotherapy when compared to
open lobectomy. Despite a 20 years period of development
and published reports of thousands of cases, VATS-L re-
mains a technique adopted by a minority of thoracic sur-
geons, at least when we look to national database;
moreover, VATS-L have experienced only in the last years
a significant increase of its uptake [7]. VMPRs are still
considered complex and demanding procedures charac-
terized by the need of a fine dissection of delicate and vul-
nerable vascular structures at risk for potential severe and
life threatening bleedings. The LC period is considered
the period more at risk for these complications. The ad-
equacy of the oncological result is the other side of the
coin. Even if several authoritative authors [14, 16, 17]
demonstrated the efficacy of VATS-L in terms of onco-
logical results and validity of intra-operative staging, the
issue is still debated. Particularly, the safety and effective-
ness of VATS mediastinal lymphadenectomy outside spe-
cialty centers or during the LC period is considered a
critical point; in these settings, some technical difficulties,
such as lymph node exposure and en bloc dissection,
could be time consuming or considered as risky, thus
leading to an oncologically inadequate result. Actually, an
incomplete mediastinal lymph node dissection/sampling
in NSCLC, may result in an incorrect staging and patients
would be denied significant chances of cure (i.e. adjuvant
chemotherapy in stage IIA and higher). For these reasons
VMPRs are not evenly spread among thoracic surgeons,
despite obvious advantages.
We planned our VATS-L program in 2011, based on
our previous experience with minimally invasive tech-
nique. We decided to select two staff surgeons and two
residents, on the basis of their skills in complex VATS
procedures different from VMPRs. This was done not
only to take advantage from the previously acquired
skills, but mainly to avoid cultural prejudices against
VATS-L, potentially present in a heterogeneous (with re-
gard to age and cultural background) surgical division.
Therefore, they were involved in qualified VATS-L train-
ing courses. We started our VATS major pulmonary re-
section program in June 2012, achieving the fifty
procedures of the expected LC in about 12 months, with
a number of at least 4 lobectomies per months; this
number allowed the attainment and maintenance of
learned skills. There are many other human factors that
may influence the LC and consequently the success of a
Table 3 Operative, post-operative data, morbidity, mortality
Variable Group A (LC) Group B p
Operative time 190,9 ± 41,4 162 ± 47,4 < 0,01
Estimated blood loss 154 ± 152 122 ± 69 NS 0,08
Conversion rate 4 (8 %) 1 (1.1 %) 0.04
Chest tube duration 5,4 ± 1,8 5,1 ± 1 NS
Hospitalization 6,47 ± 2,5 5,92 ± 1,9 NS
Post-operative complications 6 (12 %) 10 (10.6 %) NS
• Bleeding requiring transfusions 1 (2 %) 1 (1.1 %)
• Prolonged air leak 1 (2 %) 4 (4.2 %)
• Atrial arrhythmia 1 (2 %) 3 (3.1 %)
• Acute lung injury 0 1 (1.1 %)
• Liver failure and Adult
Respiratory Distress Syndrome
0 1 (1.1 %)
• Pneumonia 1 (2 %) 0
• Recurrent laryngeal nerve palsy 1 (2 %) 0
• Hoarseness with normal vocal
cord motility
1 (2 %) 0
Mortality (60 days) 0 (0 %) 1 (1.1 %) NS
NS not significant
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VATS-L program. First, the thoracoscopic experience of
the whole surgical team, including anesthesiologists
and nurses. The surgeons should have performed a
considerable number of VATS procedure (e.g. wedge
resections, mediastinal procedures, debridement of
pleural empyema) but also should have a solid thoraco-
tomic background, helpful to prevent and to solve any
intra-operative complication. Another key point is the
attendance of qualified courses in VATS-L or in centers
with a high VATS-L volume. Creating a motivated and
supportive team is crucial.
From the technical point of view, our series differs from
other authors [9–11], even in the LC, for the prevalence of
upper lobectomies (54 %: right upper lobectomy n = 48/
32 % and left upper lobectomy n = 31/21 %) that are con-
sidered technically harder than lower lobectomies, thus
influencing our operative time and conversion rate at least
at the beginning. During the LC we strictly adopted the in-
clusion criterion of clinical Stage I NSCLC, in order to
minimize the risk of complications. However, an incom-
pletion fissure at pre-operative scan was not considered a
controindication, as well as we did not start including only
lower lobe lobectomies; on the contrary, we experienced
lower lobectomies with incomplete/absent fissure as the
more complex procedures. As it happens for all surgical
procedures, their repetition and re-iterativity allows a
shorter and effective LC. By shifting to our VATS-L pro-
gram all the suitable Stage I NSCLCs, we wanted to in-
crease the frequency of VATS-L during the LC period, so
helping the surgical team in its growth. Clearly the surgical
volume of the center, first affect the length of the LC; our
500 (approximately) procedures per year ensured us a
Fig. 2 Intraoperative estimated blood loss, expressed in ml, for each patient
Fig. 1 Operative time for each patient
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sufficient volume. A surgical LC can be considered as
completed when parameters and results are stable, reach-
ing a steady state and becoming comparable with litera-
ture data. Operative time, conversion and complication
rate, hospital stay, oncologic adequacy and number of dis-
sected lymph node stations are considered critical data
during a VATS-L program. Our study showed that: 1) our
LC results are in line with literature; 2) performance indi-
cators can improve with increasing experience, maintain-
ing oncological adequacy while enlarging indications
(Table 3). Actually, operative time and conversion rate
were significantly lower after the advised fifty procedures,
whereas we noted a statistically significant improvement
in the number of dissected lymph node stations. About
lymph node dissection, the fear of not being effective,
overall during the LC period, has proved to be baseless.
Even if lymphadenectomy improves after completion of
the LC, as we expected, however a mean number of dis-
sected lymph node stations >5 demonstrates VATS effect-
iveness also during the LC.
Our policy for chest tube removal (no air leak; <200 ml/
24 h) is quite common. The incidence of prolonged air leak
is low, about 3 %, and so does not influence the mean hos-
pital stay. However our chest drain duration and
hospitalization is longer than another VATS-L series both,
during learning curve and after its completion [16]. These
data reflect more the presence of different cultural back-
grounds in our surgical team than a careful chest tube
management policy. Our team is heterogeneous and con-
sists of surgeons who have embraced the “minimally inva-
sive philosophy” and other “traditional” surgeons for which
is not possible and unthinkable an early chest tube removal
and patients discharge before the fourth post-operative day.
Data from literature showed conversion rates to thor-
acotomic lobectomy in a range between 2 and 10-12 %
[2, 14, 17]. Causes of conversion are various and re-
ported as technical problems (e.g. poor visualization,
instrumentation malfunction), anatomical problems
(calcified peri-arterial lymph nodes, absent fissure, ad-
hesions), intra-operative complications (massive bleed-
ing from vascular injury) and oncological situation
(invasion of chest wall, invasion of vascular structures,
intra-operative unexpected N2 status, centrally located
tumor, sleeve resection). Some of these factors are ab-
solutely random and stochastic and surgeon can only
prevent these problems with an accurate pre-operative
study including patients’ characteristics, radiological
and endoscopic findings that could anticipate intra-
operative critical technical aspects. A relative contra-
indication to VMPRs is considered the presence of hilar
and perivascular calcification, since it may lead to a
technical demanding vascular dissection with an in-
creased risk of major bleedings; we faced this condition
in 1.1 % of cases in Group B. In a large recent series
Villamizar et al. [18], reported an overall conversion
rate of 4 % (36/916), caused in 21 patients (2 %) by an
intra-operative bleeding; they also found a significant
relation with the presence of positive lymph node sta-
tions (n = 11 conversions in 153 clinical N+ patients/
7.2 % vs n = 25 in 763 clinical N0 patients/3.3 %). In
our series, in Group A we observed three conversions
(6 %) due to “bleeding not safely manageable by VATS”;
in our opinion this datum reflects a low experience in
bleeding management by VATS and is influenced also
by an attitude to an immediate conversion rather than
an attempt of repair (quite normal during the LC
period). However, our series demonstrated that an
emergency conversion is not a frequent event (1/146,
0.7 %), even in the early LC (1/50, 2 %). Actually, we
consider the wrong transection of the main pulmonary
artery, performed during a left upper lobe lobectomy,
as the worst complication of the whole series. Obvi-
ously, with the increased proficiency, we believe it is
ethically correct to propose VMPRs even in patients
with co-morbid disease (e.g. low pulmonary reserve),
previously treated with neo-adjuvant chemotherapy or
with surgically treatable advanced disease (T3 or T4).
In our experience we started to “extend” indications
after the conclusion of the LC, when the acquired skills
and results made us more confident in our technical
skills: in Group B we performed 6.3 % of VMPRs after
induction chemotherapy and we pushed the indications
beyond the limit of a standard lobectomy (pneumonec-
tomy 1.1 %, bilobectomy 1.1 %, chest wall resection
1.1 %), without increasing procedure-related complica-
tions or decreasing oncological adequacy.
The critical point, widely debated in literature, is the
oncologic adequacy of VMPRs. Watanabe et al. in 2005
[19] and more recently Stephens et al. [20] compared
lymph nodes number and upstaging between VATS and
open lobectomy for NSCLC and they found no signifi-
cant differences [9, 16, 19–21]. Other studies demon-
strated that the LC had no negative impact on lymph
node number or dissected nodal stations, remaining al-
ways oncologically effective [9]; our results are in line
with this literature with no differences before and after
accomplishment of the LC (Table 2).
To better understand results, we believe that collect,
analyze and compare data is basic; moreover, the oppor-
tunity to compare your results with other reliable data
from official database has an added value. In January 2014,
Crisci R. (University of L’Aquila, Italy), bringing together
the Italian centers performing VMPRs, created a VATS-L
Italian community (www.vatsgroup.org), in order to pro-
mote the diffusion of VATS-L, collect and analyze surgical
and oncological data coming from the participating cen-
ters. We think that this step will lead to a professional
growth and expansion of the Italian VATS-L community.
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Our study had some limitations: 1) is a single institu-
tion series, retrospectively analyzed in a short period
and with limited oncological follow-up; 2) obviously,
during the LC we selected patients with early stage lung
cancer and this issue can be interpreted as methodo-
logical bias; 3) furthermore there are not standardized
parameters to evaluate and quantify the surgeons’ per-
formance, proficiency and efficiency.
Conclusions
We conclude that the safety and effectiveness of a
VATS-L program with a learning curve of 50 cases per-
formed by a dedicated surgical team has been confirmed
by our study. Besides the LC, conversion rate falls down,
lymphadenectomy become more efficient, indications
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